Skip to Content
Merck
  • Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.

Epigenetic loss of heterogeneity from low to high grade localized prostate tumours.

Nature communications (2021-12-17)
Sebnem Ece Eksi, Alex Chitsazan, Zeynep Sayar, George V Thomas, Andrew J Fields, Ryan P Kopp, Paul T Spellman, Andrew C Adey
ABSTRACT

Identifying precise molecular subtypes attributable to specific stages of localized prostate cancer has proven difficult due to high levels of heterogeneity. Bulk assays represent a population-average, which mask the heterogeneity that exists at the single-cell level. In this work, we sequence the accessible chromatin regions of 14,424 single-cells from 18 flash-frozen prostate tumours. We observe shared chromatin features among low-grade prostate cancer cells are lost in high-grade tumours. Despite this loss, high-grade tumours exhibit an enrichment for FOXA1, HOXB13 and CDX2 transcription factor binding sites, indicating a shared trans-regulatory programme. We identify two unique genes encoding neuronal adhesion molecules that are highly accessible in high-grade prostate tumours. We show NRXN1 and NLGN1 expression in epithelial, endothelial, immune and neuronal cells in prostate cancer using cyclic immunofluorescence. Our results provide a deeper understanding of the active gene regulatory networks in primary prostate tumours, critical for molecular stratification of the disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Neuroligin-1, clone 1C9.1 Antibody, clone 1C9.1, from mouse
Sigma-Aldrich
Anti-pan Neurexin-1 Antibody, from rabbit, purified by affinity chromatography